Inflammasome Therapeutics to present K8 Phase 2 analyses at AAO Retina Subspecialty Day

Inflammasome Therapeutics will present additional analyses from its Phase 2 study of K8 in geographic atrophy at the American Academy of Ophthalmology Retina Subspecialty Day on Oct. 9, 2026. The six-month study evaluated K8 in 30 participants with bilateral geographic atrophy.